SCHEMBL20135459

SCHEMBL20135459

Cc1ccc(CC2CCN(C(=O)c3ccc(C4(C(C)C)NC(=O)NC4=O)cc3)C2)c(C)c1

nearest known ligand 0.38

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ADAMTS5 Q9UNA0 4/20 0.36
ADAM17 P78536 3/20 0.36
MEN1 O00255 4/20 0.36
KMT2A Q03164 4/20 0.36
LMNA P02545 2/20 0.35
ALDH1A1 P00352 1/20 0.35
CYP3A4 P08684 1/20 0.35
GAA P10253 1/20 0.35
HPGD P15428 1/20 0.35
CYP2C19 P33261 1/20 0.35
HTT P42858 1/20 0.35
SMN1; SMN2 Q16637 1/20 0.35
NPSR1 Q6W5P4 1/20 0.35
MCHR1 Q99705 1/20 0.35
GRIN2B Q13224 2/20 0.35
CRBN Q96SW2 2/20 0.34
MMP2 P08253 1/20 0.34
MMP13 P45452 1/20 0.34
CNR2 P34972 1/20 0.33
KDM1A O60341 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL20135456 1.00 ADAMTS5 (0.36) ADAMTS5ADAM17MEN1KMT2ALMNA
SCHEMBL20134777 0.82 KMT2A (0.44) MEN1KMT2ALMNAALDH1A1CYP3A4
SCHEMBL20134779 0.82 KMT2A (0.44) MEN1KMT2ALMNAALDH1A1CYP3A4
SCHEMBL20135716 0.77 KMT2A (0.61) MEN1KMT2ALMNAALDH1A1SMN1; SMN2
SCHEMBL20135714 0.77 KMT2A (0.61) MEN1KMT2ALMNAALDH1A1SMN1; SMN2
SCHEMBL20135536 0.76 MAPK7 (0.39) ADAMTS5ADAM17MEN1KMT2AALDH1A1
SCHEMBL29689296 0.76 MAPK7 (0.39) ADAMTS5ADAM17MEN1KMT2AALDH1A1
SCHEMBL20135708 0.76 PIK3CD (0.41)
SCHEMBL20134883 0.76 CCNK (0.44)
SCHEMBL20135703 0.76 PIK3CD (0.41)

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-10407408-B2 Imide derivatives and use thereof as medicine MITSUBISHI TANABE PHARMA CORPORATION (JP) 2019-09-10 US disclosed
US-20190077787-A1 NOVEL IMIDE DERIVATIVES AND USE THEREOF AS MEDICINE MITSUBISHI TANABE PHARMA CORPORATION (JP) 2019-03-14 US disclosed
EP-3321256-A1 NOVEL IMIDE DERIVATIVES AND USE THEREOF AS MEDICINE Mitsubishi Tanabe Pharma Corporation (JP) 2018-05-16 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20190077787-A1 NOVEL IMIDE DERIVATIVES AND USE THEREOF AS MEDICINE MMP9, MMP10, MMP1 ADAMTS5 23/4885ADAM17 36/4885MEN1 3735/4885
US-10407408-B2 Imide derivatives and use thereof as medicine MMP9, MMP2, MMP1 ADAMTS5 25/4885ADAM17 39/4885MEN1 2913/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.